ArticleNature communications2025
Structure-guided design of endosomolytic chloroquine-like lipid nanoparticles for mRNA delivery and genome editing.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Progress on quinoline‑based antitumour agents: Mechanistic insights and optimization strategies (Review).Molecular medicine reports · 2026Review
- BMP-7 mRNA delivered by Fibrin-CaP scaffolds activates osteogenic programs in vivo as evidenced by transcriptomic and proteomic analyses.Bioactive materials · 2026Article
- Bioactive lipid-derived nanoparticles for RNA delivery.Materials today (Kidlington, England) · 2026Article
- The Effect of Ligand Reactivity and Carrier Mechanics on Thiol-Mediated Cellular Uptake for miRNA Nano-Drugs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mechanical movements generated by movable lipids break endosomal barriers for enhanced mRNA therapeutics.Science advances · 2026Article
- Preformulated, Shelf-Stable, Dendritic Cell-Targeting Nanogel mRNA Vaccine Delivery Platform.Bioconjugate chemistry · 2026Article
- Mechanistic Insight Into Ionizable Cationic Lipid-Mediated Endosomal Escape via Transient Lipid Complexes.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Mechanistic insights into mRNA-LNP interactions: role of ionizable lipid content in regulating mRNA intracellular release and translation.Journal of nanobiotechnology · 2026Article
- mRNA vaccines for HBV: Mechanisms, preclinical advances, and therapeutic clinical progress.Molecular therapy. Nucleic acids · 2026Review
- Nanostructured branched Y-DNA promotes antitumor immunity through dual activation of cGAS/STING and TLR9.Archives of pharmacal research · 2026Article
- Ocular delivery of lipid nanoparticles-formulated mRNA encoding lanosterol synthase ameliorates cataract in rats.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite remarkable progress in designing RNA delivery systems, endosomal escape remains a recognized challenge for efficient RNA delivery. In this study, we develop a robust mRNA delivery platform termed endosomolytic chloroquine-like optimized lipid nanoparticles (ecoLNPs) for versatile mRNA delivery in vitro and in vivo via integrating the signature scaffold extracted from endosomolytic chloroquine into ionizable lipids. RNase-resistant ecoLNPs are capable of delivering a broad variety of mRNA payloads to diverse cell types, even hard-to-transfect 3D cells, with an efficiency of up to 18.9-fold higher than that of commercial transfection reagents. The pH-responsive endosomolytic activity of ecoLNPs can be largely attributed to the proton sponge effect and saposin B-promoted membrane disruption. In vivo, ecoLNPs enable potent local and systemic mRNA delivery and exhibit comparable potency to the clinically approved mRNA vaccine carrier, but strong tropism for lymph nodes following intramuscular injection. Furthermore, ecoLNPs are able to retain in vivo delivery potency for at least one week under non-frozen conditions and induce efficient genome editing in transgenic mice. Overall, the structure-guided integration strategy provides a pathway for de novo design of endosomolytic mRNA delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.